ICU Medical - ICUI Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $127.00
  • Forecasted Upside: 0.81%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$125.98
▼ -2.25 (-1.75%)

This chart shows the closing price for ICUI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ICU Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICUI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICUI

Analyst Price Target is $127.00
▲ +0.81% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for ICU Medical in the last 3 months. The average price target is $127.00, with a high forecast of $136.00 and a low forecast of $110.00. The average price target represents a 0.81% upside from the last price of $125.98.

This chart shows the closing price for ICUI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in ICU Medical. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/21/2024Needham & Company LLCInitiated CoverageHoldLow
6/17/2024Raymond JamesUpgradeMarket Perform ➝ Outperform$135.00Low
2/28/2024KeyCorpBoost TargetOverweight ➝ Overweight$134.00 ➝ $136.00Low
2/6/2024KeyCorpInitiated CoverageOverweight$134.00Low
12/14/2023CL KingInitiated CoverageBuy$110.00Low
5/9/202351jobReiterated RatingMaintainsLow
5/9/2023KeyCorpBoost Target$200.00 ➝ $216.00Low
11/8/2022KeyCorpLower Target$225.00 ➝ $200.00Low
11/8/2022Raymond JamesDowngradeOutperform ➝ Market PerformLow
8/9/2022KeyCorpLower Target$230.00 ➝ $225.00Low
8/9/2022Raymond JamesLower TargetOutperform$208.00 ➝ $190.00Low
8/3/2022KeyCorpLower TargetOverweight$265.00 ➝ $230.00Low
2/28/2022Raymond JamesLower TargetOutperform$286.00 ➝ $265.00High
10/22/2021KeyCorpLower TargetOverweight$302.00 ➝ $280.00Low
9/9/2021KeyCorpBoost TargetOverweight$225.00 ➝ $302.00Medium
9/9/2021Raymond JamesBoost TargetOutperform$220.00 ➝ $286.00Medium
8/6/2021KeyCorpLower TargetOverweight$236.00 ➝ $225.00Low
8/5/2021Raymond JamesLower TargetOutperform$245.00 ➝ $220.00Medium
2/26/2021Raymond JamesBoost TargetOutperform$235.00 ➝ $245.00High
2/11/2021Raymond JamesBoost TargetOutperform$210.00 ➝ $235.00Low
1/8/2021KeyCorpBoost TargetOverweight$222.00 ➝ $236.00Medium
12/17/2020Raymond JamesReiterated RatingBuyHigh
11/6/2020KeyCorpBoost TargetOverweight$218.00 ➝ $222.00Low
9/2/2020KeyCorpBoost TargetOverweight$199.00 ➝ $218.00Low
8/11/2020Raymond JamesLower TargetOutperform$228.00 ➝ $210.00High
5/13/2020KeyCorpLower TargetOverweight$206.00 ➝ $199.00High
5/8/2020Raymond JamesBoost TargetOutperform$215.00 ➝ $228.00High
3/31/2020CJS SecuritiesUpgradeMarket Perform ➝ OutperformMedium
3/18/2020KeyCorpUpgradeSector Weight ➝ Overweight$206.00High
2/28/2020Raymond JamesBoost TargetOutperform$203.00 ➝ $215.00High
11/12/2019Raymond JamesBoost TargetOutperform ➝ Positive$185.00 ➝ $203.00High
9/6/2019Raymond JamesSet TargetBuy$185.00Low
8/8/2019Raymond JamesDowngradeStrong-Buy ➝ OutperformHigh
(Data available from 7/14/2019 forward)

News Sentiment Rating

1.38 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/15/2024
  • 13 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/15/2024
  • 12 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/15/2024
  • 14 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/14/2024
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/14/2024

Current Sentiment

  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
ICU Medical logo
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Read More

Today's Range

Now: $125.98
Low: $125.70
High: $130.28

50 Day Range

MA: $111.60
Low: $100.60
High: $128.23

52 Week Range

Now: $125.98
Low: $78.28
High: $182.62

Volume

247,516 shs

Average Volume

422,531 shs

Market Capitalization

$3.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of ICU Medical?

The following Wall Street analysts have issued research reports on ICU Medical in the last twelve months: CL King, KeyCorp, Needham & Company LLC, Raymond James, StockNews.com, and TheStreet.
View the latest analyst ratings for ICUI.

What is the current price target for ICU Medical?

3 Wall Street analysts have set twelve-month price targets for ICU Medical in the last year. Their average twelve-month price target is $127.00, suggesting a possible upside of 0.8%. KeyCorp has the highest price target set, predicting ICUI will reach $136.00 in the next twelve months. CL King has the lowest price target set, forecasting a price of $110.00 for ICU Medical in the next year.
View the latest price targets for ICUI.

What is the current consensus analyst rating for ICU Medical?

ICU Medical currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ICUI.

What other companies compete with ICU Medical?

How do I contact ICU Medical's investor relations team?

ICU Medical's physical mailing address is 951 CALLE AMANECER, SAN CLEMENTE CA, 92763. The medical instruments supplier's listed phone number is (949) 366-2183 and its investor relations email address is [email protected]. The official website for ICU Medical is www.icumed.com. Learn More about contacing ICU Medical investor relations.